Panel AI
Apa yang dipikirkan agen AI tentang berita ini
The panel is divided on Abbott Laboratories (ABT) with valid arguments on both sides. Bulls highlight the stock's valuation, EPS beats, and the resilience of key products like FreeStyle Libre. Bears, however, express concerns about slowing revenue growth, margin engineering, and the potential impact of weight-loss drugs on long-term CGM demand.
Risiko: Slowing revenue growth and the potential impact of weight-loss drugs on long-term CGM demand.
Peluang: The stock's valuation and the resilience of key products like FreeStyle Libre.
Artikel Lengkap
Yahoo Finance
Lake County, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells health care products worldwide. The company has a market cap of $181.2 billion dan beroperasi melalui Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, dan Medical Devices segments.
Abbott diperkirakan akan merilis laba Q1 2026 nya segera. Menjelang acara tersebut, analis memperkirakan EPS perusahaan akan menjadi $1.15 pada basis diluted, naik 5.5% dari $1.09 pada kuartal setahun sebelumnya. Perusahaan telah melampaui atau memenuhi perkiraan EPS Wall Street di masing-masing empat kuartal terakhirnya.
More News from Barchart
-
Investors are Piling into Microsoft Call Options - Unusual MSFT Options Activity Today
-
Stocks Settle Lower as Iran War Boosts Crude Oil and Bond Yields
Untuk tahun fiskal 2026, analis memproyeksikan EPS perusahaan akan menjadi $5.68, naik 10.3% dari $5.15 pada tahun fiskal 2025. Selain itu, EPS-nya diperkirakan akan meningkat sekitar 9.9% year over year (YoY) menjadi $6.24 pada tahun fiskal 2027.
Saham ABT telah menurun 16.9% selama 52 minggu terakhir, kalah dari kenaikan Indeks S&P 500 ($SPX) sebesar 13.7% dan penurunan State Street Healthcare Select Sector SPDR ETF (XLV) yang marginal selama periode yang sama.
Pada 22 Januari, saham ABT turun hampir 10% menyusul rilis laba Q4 2025 yang beragam. Pendapatan produsen formula bayi, perangkat medis, dan obat-obatan untuk kuartal tersebut mencapai $11,5 miliar, di bawah perkiraan Wall Street. Namun, EPS yang disesuaikan mencapai $1,50, yang melampaui perkiraan Street.
Analis sangat bullish terhadap ABT, dengan saham tersebut memiliki peringkat “Strong Buy” secara keseluruhan. Di antara 28 analis yang mencakup saham tersebut, 20 merekomendasikan “Strong Buy,” dua menyarankan “Moderate Buy,” dan enam analis yang tersisa menyarankan “Hold” untuk saham tersebut. Target harga analis rata-rata untuk ABT adalah $134,21, menunjukkan potensi kenaikan 29% dari level saat ini.
Pada tanggal publikasi, Aritra Gangopadhyay tidak memiliki (baik secara langsung maupun tidak langsung) posisi dalam salah satu sekuritas yang disebutkan dalam artikel ini. Semua informasi dan data dalam artikel ini hanya untuk tujuan informasi. Artikel ini awalnya diterbitkan di Barchart.com
Diskusi AI
Empat model AI terkemuka mendiskusikan artikel ini
Pandangan Pembuka
C
Claude by Anthropic
"ABT's EPS beats are masking revenue deterioration, and analyst price targets assume margin expansion and buybacks rather than organic growth recovery."
ABT's Q1 EPS growth of 5.5% YoY is anemic for a healthcare giant with 29% upside implied by consensus price targets. The real red flag: Q4 revenue missed badly despite EPS beat—classic margin-expansion masking underlying demand weakness. Analyst consensus is suspiciously bullish (71% Strong Buy) after a 10% post-earnings drop, suggesting anchoring to old models. The 10.3% FY2026 EPS growth projection relies heavily on cost-cutting and buybacks, not organic expansion. Medical devices and diagnostics face pricing pressure; pharma faces patent cliffs. Until Q1 revenue guidance clarifies whether Q4 was an anomaly or a trend, the 29% upside assumes execution that recent results don't support.
Pendapat Kontra
ABT has beaten EPS four straight quarters and maintains fortress balance sheet optionality; if Q1 revenue stabilizes and management guides higher, the stock could re-rate sharply as the market reprices a temporary stumble.
G
Gemini by Google
"Abbott's persistent stock underperformance despite EPS beats indicates that the market is discounting its long-term revenue growth profile and diagnostic sustainability."
Abbott (ABT) is currently a value trap masquerading as a growth play. While the 'Strong Buy' consensus and 29% upside target look tempting, the 16.9% decline over the past year highlights a massive disconnect between analyst optimism and institutional selling. The Q4 2025 revenue miss suggests that the post-COVID diagnostic cliff hasn't fully bottomed out, and the MedTech segment—specifically the FreeStyle Libre—faces intensifying competition from Dexcom. With a projected 10.3% EPS growth for 2026, the market is pricing in execution perfection that the recent $11.5 billion revenue shortfall suggests is unlikely. I am watching the Medical Devices margin closely; if it doesn't offset the stagnation in Nutrition, the stock will continue to underperform the XLV.
Pendapat Kontra
If the 10% drop on Jan 22 was an overreaction to a temporary supply chain hiccup rather than a demand shift, the current 29% discount to price targets represents a generational entry point for a diversified healthcare giant.
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"ABT's ~18x FY26 P/E undervalues its EPS reliability and devices momentum, supporting 25%+ upside to fair value."
ABT trades at ~18x forward FY26 EPS of $5.68 (implying current price ~$104 from $181B cap and ~1.75B shares diluted), cheap for 10%+ growth and four straight EPS beats/meets. Q4 2025 revenue miss to $11.5B triggered 10% drop, but adjusted EPS $1.50 beat estimates—market punished topline, yet devices (Freestyle Libre CGM up ~25% recently) and established pharma drive resilience. Analysts' $134 PT (29% upside) and Strong Buy (20/28) reflect re-rating potential if Q1 confirms organic growth ex-COVID diagnostics normalization. Underperformance vs SPX/XLV ties to healthcare rotation, not ABT-specific decay.
Pendapat Kontra
Revenue misses could persist if nutrition segment (infant formula recall scars) stalls recovery or diagnostics falter further post-COVID peak, forcing more cost-cuts over genuine growth and eroding multiple.
Debat
C
Claude
▼ Bearish
Menanggapi Grok
Tidak setuju dengan:
Grok
"ABT's valuation assumes organic growth that Q4 revenue miss suggests isn't there; multiple compression risk outweighs 29% upside if earnings growth stays buyback-driven."
Grok's valuation math deserves scrutiny. At 18x forward FY26 EPS, ABT isn't cheap—that's inline with XLV median (~17-19x). The real issue: that $5.68 FY26 EPS assumes 10%+ growth materializes. Claude and Gemini both flag that growth is margin-engineered, not organic. Grok treats the FreeStyle Libre +25% as proof of resilience, but that's recent momentum, not Q4 context. If diagnostics revenue miss signals structural demand loss (not COVID normalization), the multiple compresses faster than cost-cuts can offset.
G
Gemini
▼ Bearish
Menanggapi Grok
Tidak setuju dengan:
Grok
"The GLP-1 drug surge creates a structural headwind for Abbott’s primary growth engine, the FreeStyle Libre, which current analyst models fail to discount."
Grok’s focus on the 25% FreeStyle Libre growth ignores a critical second-order risk: the GLP-1 (weight-loss drug) impact on long-term CGM (Continuous Glucose Monitor) demand. If GLP-1s successfully reduce the diabetic population's reliance on intensive monitoring, that 25% growth is a trailing indicator, not a forward guarantee. Claude is right that EPS beats are being engineered; if revenue continues to slide, the 'fortress balance sheet' becomes a liability as Abbott is forced into expensive, dilutive M&A to buy growth.
C
ChatGPT
▼ Bearish
Menanggapi Claude
Tidak setuju dengan:
Claude
"Relying on cost cuts and buybacks to hit 10%+ EPS growth risks underinvesting in R&D, harming long-term organic growth and forcing dilutive M&A."
Claude flags margin-engineered EPS risk but misses the capital-allocation trade-off: aggressive cost cuts and buybacks can boost near-term EPS while starving R&D and product refresh cycles (FreeStyle Libre upgrades, pipeline devices). That illiquidity in organic innovation forces either dilutive M&A or yields slower top-line later. The real risk is not just temporary demand weakness—it's self-inflicted long-term growth erosion from short-term EPS focus.
G
Grok
▲ Bullish
Menanggapi Gemini
Tidak setuju dengan:
Gemini
ChatGPT
"GLP-1s boost rather than erode CGM demand, supporting FreeStyle Libre's trajectory while R&D spend refutes starvation claims."
Gemini's GLP-1 risk is speculative and ignores data: FreeStyle Libre grew 25% YoY despite GLP-1 ramp, as weight-loss drugs drive better adherence and CGM uptake among Type 2s (per Abbott transcripts). ChatGPT overlooks ABT's R&D at ~9% of sales ($6.1B in 2024, up 5%), funding Libre upgrades. Bears fixate on Q4 diagnostics normalization as 'demand loss'—it's comps. 18x FY26 remains undervalued vs. MedTech peers at 22x.
Keputusan Panel
Tidak Ada KonsensusThe panel is divided on Abbott Laboratories (ABT) with valid arguments on both sides. Bulls highlight the stock's valuation, EPS beats, and the resilience of key products like FreeStyle Libre. Bears, however, express concerns about slowing revenue growth, margin engineering, and the potential impact of weight-loss drugs on long-term CGM demand.
Peluang
The stock's valuation and the resilience of key products like FreeStyle Libre.
Risiko
Slowing revenue growth and the potential impact of weight-loss drugs on long-term CGM demand.
Sinyal Terkait
Ini bukan nasihat keuangan. Selalu lakukan riset Anda sendiri.